There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia.
Study Type
OBSERVATIONAL
Enrollment
15
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
RECRUITINGThe virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1
The SARS-CoV-2 nuclei acid was quantified using RT-PCR
Time frame: 1 day after receiving plasma transmission
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3
Time frame: 3 days after receiving plasma transmission
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7
Time frame: 7 days after receiving plasma transmission
Numbers of participants with different Clinical outcomes
Clinical outcomes include death, critical illness, recovery
Time frame: From receiving plasma transmission to 4 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: 4 weeks after receiving plasma transmission
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.